On-demand Session: CMC Management for Oligonucleotide Therapeutics: Bridging Research to Clinical

uRNA: has a strong intrinsic adjuvant effect, with strong antibody response, generating CD8+T cells CD4+T cells;
modRNA: has moderate intrinsic adjuvant effect, with a very strong antibody response and lower cytokine induction, generating CD4+T cells CD8+T cells;
saRNA: has a long duration, a higher likelihood for good efficacy antibody response even when using a lower dosage.

by Toru Okamatsu, Manager of Business Development, Ajinomoto Bio-Pharma Services

CMC Management for Oligonucleotide Therapeutics: Bridging Research to Clinical

A well-designed CMC strategy is essential when developing oligonucleotide therapeutics. With over 20 years of focused experience and application, Ajinomoto Bio-Pharma Services offers oligonucleotide development services and manufacturing know-how and capabilities ranging from research to commercial needs.This presentation examines potential CMC gaps occurring between research to early clinical stages, helping to improve project design and management from a CMC perspective.

Find out more at ajibio-pharma.com.